Medicare beneficiaries who rely on GLP-1 medications for weight loss now have a new option after years of paying out of pocket. Starting July 1, 2026, the Centers for Medicare & Medicaid Services introduced the Medicare GLP-1 Bridge, a temporary program offering eligible Part D enrollees select weight-loss drugs for a flat $50 monthly copay.
The program operates outside the standard Part D system.
It uses a separate claims processor handling prior authorizations, payments, and pharmacy reimbursements. Prescriptions filled through the Bridge won’t interact with a beneficiary’s regular Part D plan, and insurers bear no financial risk for these claims.
Related: Web users blocked from certain sites
Originally intended as a stopgap until the broader BALANCE program took effect in 2027, the Bridge was extended through December 31, 2027. CMS delayed the Part D portion of BALANCE indefinitely after insurers expressed concerns about its rollout. This left the Bridge as the only federal pathway for weight-loss GLP-1s in Medicare for the time being.
Pharmacies process Bridge claims using a dedicated Bank Identification Number (BIN 028918) and Processor Control Number (PCN MEDDGLP1BR). Submitting a claim through standard Part D channels will result in rejection, a detail already causing confusion for some prescribers and patients.
The Bridge covers three medications: Wegovy (semaglutide) in injectable and tablet forms, Zepbound (tirzepatide) in the KwikPen formulation only, and all formulations of Foundayo. Single-dose vials and pens of Zepbound aren’t eligible, nor are GLP-1s prescribed for diabetes, cardiovascular risk, sleep apnea, or metabolic dysfunction-associated steatohepatitis. Those conditions remain under standard Part D coverage.
Eligibility depends on a patient’s clinical status when they started GLP-1 therapy, not their current condition. For instance, someone who began treatment with a BMI of 37 but later reached a BMI of 31 may still qualify if their prescriber confirms the original BMI threshold.
Related: Pharmacists Offer Practical Tips to Prevent Drink Spiking
To qualify, beneficiaries must be enrolled in a standalone Part D plan or a Medicare Advantage plan with drug coverage and meet one of these criteria:
- BMI of 35 or higher;
- BMI of 30 or higher plus heart failure with preserved ejection fraction, uncontrolled hypertension despite treatment, or chronic kidney disease (stage 3a or above); or
- BMI of 27 or higher plus prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.
Those in private fee-for-service plans, Programs of All-Inclusive Care for the Elderly, or fallback plans don’t qualify.
The program balances access and cost control. By limiting coverage to weight loss and excluding other indications, CMS avoids the higher costs of drugs like Ozempic and Mounjaro, which are prescribed for diabetes and other conditions. However, the separate claims pathway means the $50 copay doesn’t count toward the Part D out-of-pocket cap, which could surprise some patients.
Related: Account Blocked After Policy Violation
Formulation details also matter. Patients assuming any version of Zepbound is covered may be surprised to learn only the KwikPen qualifies. The single-dose vial and pen are excluded, a distinction already causing confusion at pharmacies.
The Bridge marks the first time Medicare has provided a structured pathway for weight-loss GLP-1s.
Its temporary status leaves long-term access uncertain. For now, it’s the only federal option for beneficiaries who previously paid hundreds of dollars a month out of pocket. How well it functions—and whether it leads to permanent coverage—will depend on how pharmacies, prescribers, and patients adjust to its separate claims system.